Fortress Biotech Company Profile (NASDAQ:FBIO)

About Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech logoFortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:FBIO
  • CUSIP: 21976U10
  • Web: www.fortressbiotech.com
Capitalization:
  • Market Cap: $224.85 million
  • Outstanding Shares: 50,527,000
Average Prices:
  • 50 Day Moving Avg: $4.44
  • 200 Day Moving Avg: $4.12
  • 52 Week Range: $1.88 - $5.13
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.78
  • P/E Growth: -0.10
Sales & Book Value:
  • Annual Revenue: $108.97 million
  • Price / Sales: 2.09
  • Book Value: $1.43 per share
  • Price / Book: 3.15
Profitability:
  • EBIDTA: ($71,480,000.00)
  • Net Margins: -53.95%
  • Return on Equity: -54.88%
  • Return on Assets: -30.67%
Debt:
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 3.56%
  • Quick Ratio: 3.55%
Misc:
  • Average Volume: 191,659 shs.
  • Beta: 1.13
  • Short Ratio: 20.13
 

Frequently Asked Questions for Fortress Biotech (NASDAQ:FBIO)

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The business had revenue of $2.78 million for the quarter, compared to analyst estimates of $47.04 million. Fortress Biotech had a negative net margin of 53.95% and a negative return on equity of 54.88%. View Fortress Biotech's Earnings History.

When will Fortress Biotech make its next earnings announcement?

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Fortress Biotech.

Where is Fortress Biotech's stock going? Where will Fortress Biotech's stock price be in 2017?

5 brokerages have issued 12-month target prices for Fortress Biotech's shares. Their forecasts range from $9.00 to $11.00. On average, they expect Fortress Biotech's share price to reach $10.60 in the next twelve months. View Analyst Ratings for Fortress Biotech.

What are analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:

  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (9/12/2017)
  • 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)

Who are some of Fortress Biotech's key competitors?

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the folowing people:

  • Lindsay A. Rosenwald M.D., Chairman of the Board, President, Chief Executive Officer
  • Eric K. Rowinsky M.D., Vice Chairman of the Board
  • Robyn Hunter, Chief Financial Officer
  • Michael S. Weiss, Executive Vice Chairman - Strategic Development
  • Lucy Lu M.D., Executive Vice President
  • George C. Avgerinos Ph.D., Senior Vice President - Biologics Operations
  • Malcolm I. Hoenlein, Director
  • David J. Barrett CPA,, Independent Director
  • Jimmie Harvey Jr., M.D., Independent Director
  • J. Jay Lobell J.D., Independent Director

Who owns Fortress Biotech stock?

Fortress Biotech's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.56%), State Street Corp (0.93%), Northern Trust Corp (0.77%), California Public Employees Retirement System (0.25%), ClariVest Asset Management LLC (0.24%) and Bank of New York Mellon Corp (0.21%). View Institutional Ownership Trends for Fortress Biotech.

Who sold Fortress Biotech stock? Who is selling Fortress Biotech stock?

Fortress Biotech's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., ClariVest Asset Management LLC, Susquehanna International Group LLP, California State Teachers Retirement System, TIAA CREF Investment Management LLC, Teachers Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Fortress Biotech.

Who bought Fortress Biotech stock? Who is buying Fortress Biotech stock?

Fortress Biotech's stock was purchased by a variety of institutional investors in the last quarter, including Abner Herrman & Brock LLC, State Street Corp, Strs Ohio, State of Wisconsin Investment Board, National Asset Management Inc., Northern Trust Corp, Parametric Portfolio Associates LLC and Rhumbline Advisers. View Insider Buying and Selling for Fortress Biotech.

How do I buy Fortress Biotech stock?

Shares of Fortress Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of Fortress Biotech stock can currently be purchased for approximately $4.51.


MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Fortress Biotech (NASDAQ:FBIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.60 (135.03% upside)

Analysts' Ratings History for Fortress Biotech (NASDAQ:FBIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017HC WainwrightSet Price TargetBuy$11.00HighView Rating Details
7/11/2017Rodman & RenshawInitiated CoverageBuy -> Buy$11.00LowView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$11.00MediumView Rating Details
10/3/2016Roth CapitalInitiated CoverageBuy$9.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Fortress Biotech (NASDAQ:FBIO)
Earnings by Quarter for Fortress Biotech (NASDAQ:FBIO)
Earnings History by Quarter for Fortress Biotech (NASDAQ FBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.43)N/AView Earnings Details
5/10/2017Q1 2017($0.36)($0.30)$47.04 million$2.78 millionViewN/AView Earnings Details
8/9/2016Q2($0.29)($0.31)$1.07 million$2.23 millionViewN/AView Earnings Details
5/10/2016Q1($0.31)$0.66 millionViewN/AView Earnings Details
3/15/2016Q4($0.09)($0.31)$0.34 millionViewN/AView Earnings Details
11/9/2015Q315($0.13)($0.46)$0.03 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)ViewN/AView Earnings Details
5/11/2015Q1($0.31)ViewN/AView Earnings Details
3/16/2015Q414($0.10)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.17)($0.13)ViewN/AView Earnings Details
5/12/2014Q114($0.18)($0.21)ViewN/AView Earnings Details
3/14/2014Q413($0.22)($0.27)ViewN/AView Earnings Details
11/1/2013Q313($0.31)($0.24)ViewN/AView Earnings Details
8/5/2013Q213($0.31)($0.38)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.30)($0.35)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.27)($0.36)ViewN/AView Earnings Details
11/14/2012Q312($0.28)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fortress Biotech (NASDAQ:FBIO)
2017 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fortress Biotech (NASDAQ:FBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Fortress Biotech (NASDAQ:FBIO)
Insider Ownership Percentage: 31.54%
Institutional Ownership Percentage: 11.99%
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Institutional Ownership by Quarter for Fortress Biotech (NASDAQ:FBIO)
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016George AvgerinosSVPSell48,912$2.55$124,725.60View SEC Filing  
12/1/2014Lucy LuCFOBuy5,000$1.45$7,250.00View SEC Filing  
11/6/2014Lindsay A Md RosenwaldCEOBuy150,000$1.61$241,500.00View SEC Filing  
11/6/2014Malcolm HoenleinDirectorBuy25,000$1.61$40,250.00View SEC Filing  
11/6/2014Michael S WeissMajor ShareholderBuy1,000,000$1.61$1,610,000.00View SEC Filing  
6/2/2014Lucy LuCFOBuy5,000$1.37$6,850.00View SEC Filing  
4/22/2014Kevin HorganInsiderSell47,566$1.89$89,899.74View SEC Filing  
4/21/2014Kevin HorganInsiderSell19,000$1.81$34,390.00View SEC Filing  
8/21/2013J Jay LobellDirectorBuy5,000$7.37$36,850.00View SEC Filing  
7/17/2013Lucy LuCFOBuy4,545$7.90$35,905.50View SEC Filing  
6/20/2013J Jay LobellDirectorBuy10,000$7.62$76,200.00View SEC Filing  
5/31/2013Dale RitterCAOBuy1,503$3.88$5,831.64View SEC Filing  
5/31/2013Lucy LuCFOBuy4,979$3.88$19,318.52View SEC Filing  
5/31/2013Noah D BeermanCOOBuy5,000$3.88$19,400.00View SEC Filing  
1/14/2013Harlan F WeismanCEOBuy20,000$5.71$114,200.00View SEC Filing  
11/30/2012Glenn L Md CooperInsiderBuy3,811$4.02$15,320.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Fortress Biotech (NASDAQ:FBIO)
Latest Headlines for Fortress Biotech (NASDAQ:FBIO)
Source:
DateHeadline
americanbankingnews.com logoFortress Biotech (FBIO) versus MediWound (MDWD) Critical Comparison
www.americanbankingnews.com - September 17 at 4:26 AM
finance.yahoo.com logoMustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
finance.yahoo.com - September 14 at 7:15 PM
americanbankingnews.com logoFortress Biotech, Inc. (FBIO) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - September 12 at 8:24 PM
globenewswire.com logoMustang Bio to Present at the CAR-TCR Summit 2017 - GlobeNewswire (press release)
globenewswire.com - September 7 at 4:35 AM
finance.yahoo.com logoFortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 8:11 PM
americanbankingnews.com logoFortress Biotech, Inc. (FBIO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 6:46 AM
americanbankingnews.com logoChemoCentryx (CCXI) and Fortress Biotech (FBIO) Critical Analysis
www.americanbankingnews.com - August 29 at 10:42 AM
nasdaq.com logoMustang Bio Commences Trading on the NASDAQ Global Market - Nasdaq
www.nasdaq.com - August 24 at 4:58 AM
streetinsider.com logoMustang Bio (MBIO) Commences Trading
www.streetinsider.com - August 23 at 11:56 PM
globenewswire.com logoMustang Bio Commences Trading on the NASDAQ Global Market - GlobeNewswire (press release)
globenewswire.com - August 23 at 12:08 AM
finance.yahoo.com logoMustang Bio Commences Trading on the NASDAQ Global Market
finance.yahoo.com - August 22 at 7:06 PM
globenewswire.com logoAvenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate ... - GlobeNewswire (press release)
globenewswire.com - August 17 at 4:44 AM
globenewswire.com logoMustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)
globenewswire.com - August 14 at 6:55 PM
globenewswire.com logoFortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments ... - GlobeNewswire (press release)
globenewswire.com - August 14 at 6:55 PM
finance.yahoo.com logoMustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 14 at 6:55 PM
finance.yahoo.com logoFortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases
finance.yahoo.com - August 14 at 6:55 PM
finance.yahoo.com logoAvenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 11 at 7:01 PM
finance.yahoo.com logoFortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 9 at 6:43 PM
finance.yahoo.com logoFortress Biotech reports 2Q loss
finance.yahoo.com - August 9 at 6:43 PM
americanbankingnews.com logoFortress Biotech, Inc. (FBIO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 5 at 7:14 AM
americanbankingnews.com logoFortress Biotech, Inc. (FBIO) Expected to Post Quarterly Sales of $45.83 Million
www.americanbankingnews.com - July 29 at 7:21 AM
finance.yahoo.com logoCheckpoint (CKPT): An Innovator of Immune-Enhanced Combination Therapies in Solid Tumors
finance.yahoo.com - July 28 at 4:45 PM
americanbankingnews.com logoFortress Biotech, Inc. (NASDAQ:FBIO) Expected to Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - July 27 at 10:33 PM
reuters.com logoBRIEF-Fortress Biotech announces filing of provisional patent application for Caelum Biosciences' cael-101
www.reuters.com - July 18 at 12:28 AM
finance.yahoo.com logoFortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101
finance.yahoo.com - July 17 at 11:54 AM
americanbankingnews.com logoFortress Biotech, Inc. (FBIO) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 12 at 12:04 AM
americanbankingnews.com logoFortress Biotech, Inc. (NASDAQ:FBIO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 11 at 8:26 AM
americanbankingnews.com logoReviewing Catalyst Biosciences (CBIO) & Fortress Biotech (NASDAQ:FBIO)
www.americanbankingnews.com - July 4 at 6:26 PM
finance.yahoo.com logoFortress Biotech (FBIO) Shares March Higher, Can It Continue?
finance.yahoo.com - June 30 at 6:51 PM
feeds.benzinga.com logoAvenue Therapeutics Completes Initial Public Offering
feeds.benzinga.com - June 30 at 11:40 AM
finance.yahoo.com logoPharmaceuticals Abound Among This Week's 11 IPOs
finance.yahoo.com - June 27 at 10:25 PM
streetinsider.com logoAvenue Therapeutics IPO Info
www.streetinsider.com - June 27 at 5:23 PM
feeds.benzinga.com logoAvenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock
feeds.benzinga.com - June 26 at 8:36 PM
finance.yahoo.com logoCheckpoint Therapeutics Commences Trading on the NASDAQ Capital Market
finance.yahoo.com - June 26 at 6:16 PM
finance.yahoo.com logoFortress Biotech to Present at the 2017 BIO International Convention
finance.yahoo.com - June 15 at 7:16 PM
finance.yahoo.com logoMeet This Week's IPOs: A Biotech, A BDC And A Builder
finance.yahoo.com - June 13 at 11:36 AM
americanbankingnews.com logoFortress Biotech, Inc. (FBIO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - June 13 at 10:04 AM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 7 at 3:32 PM
finance.yahoo.com logoFortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies
finance.yahoo.com - June 5 at 11:19 AM
americanbankingnews.com logoFortress Biotech (FBIO) vs. Vitae Pharmaceuticals (VTAE) Head-To-Head Comparison
www.americanbankingnews.com - June 4 at 8:28 PM
streetinsider.com logoFortress Biotech (FBIO) Subsidiary Enters Biopharmaceutical Manufacturing Agreement With Patheon
www.streetinsider.com - June 1 at 5:52 PM
finance.yahoo.com logoFortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon
finance.yahoo.com - June 1 at 5:52 PM
finance.yahoo.com logoCheckpoint Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 5:52 PM
seekingalpha.com logoA Profitable And Growing Microcap Investment Bank Focused On The Biotech Sector
seekingalpha.com - May 31 at 10:07 PM
finance.yahoo.com logoAvenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
finance.yahoo.com - May 19 at 4:53 PM
finance.yahoo.com logoFortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session
finance.yahoo.com - May 19 at 4:53 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 15 at 8:58 PM
finance.yahoo.com logoETFs with exposure to Fortress Biotech, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:49 PM
finance.yahoo.com logoMustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 15 at 4:48 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Fortress Biotech Inc (FBIO) Boosted by FBR & Co
www.americanbankingnews.com - May 15 at 7:58 AM

Social

Chart

Fortress Biotech (FBIO) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff